Biotronik's absorbable stent shows 1-year promise:
This article was originally published in Clinica
Executive Summary
One-year follow-up data from a clinical trial of Biotronik's absorbable metal stent (AMS) are continuing to support the device, the firm has reported. The European study, which is testing the stent as a treatment for blocked arteries below the knee, revealed that after 12 months there was a primary vessel patency rate of 72.4% and a limb salvage rate of 94.7%. The Berlin, Germany firm said it was now preparing to start a randomised trial called INSIGHT-AMS within the second quarter of this year. The study, which will assess the six-month patency results of patients with infra-popliteal occlusion, is expected to result in Biotronik CE-marking the AMS technology for sale in Europe.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.